Company Overview and News
Huntington Ingalls Industries’ (NYSE: HII) piloting of new technologies as part of its digital transformation is redefining the future of the naval engineering and shipbuilding industries. The company’s Newport News Shipbuilding division, in collaboration with the U.S. Navy, has led the adoption of additive manufacturing of metal components for nuclear-powered warships.
NEWPORT NEWS, Va., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Thirteen employees from Huntington Ingalls Industries’ (NYSE:HII) Ingalls and Newport News shipbuilding divisions were recognized for their achievements in science, technology, engineering and math (STEM) during the 23nd annual Women of Color STEM Conference.
Naval Sea Systems Command (NAVSEA) approved the first metal part created by additive manufacturing (AM) for shipboard installation, the command announced Oct. 11.
NEWPORT NEWS, Va., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries’ (NYSE: HII) piloting of new technologies as part of its digital transformation is redefining the future of the naval engineering and shipbuilding industries. The company’s Newport News Shipbuilding division, in collaboration with the U.S. Navy, has led the adoption of additive manufacturing of metal components for nuclear-powered warships.
NEWPORT NEWS, Va., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) has announced the promotion of Garry Schwartz to president of the Mission Driven Innovative Solutions (HII-MDIS) group, part of its Technical Solutions division.
The subsidiary of United Launch Alliance (“ULA”) — a joint venture (JV) between Lockheed Martin Corp. (LMT - Free Report) and The Boeing Co. (BA - Free Report) — recently secured a contract involving the Evolved Expendable Launch Vehicle (EELV) program. Per the terms of the agreement, United Launch Services, LLC (“ULS”) — the subsidiary — will develop a Launch System Prototype for the EELV program.
LMT POOL HII BOE TXT BA
U.S. stocks have been on a downward trajectory for the past couple of days. On Oct 10, the Wall Street suffered its worst fall in more than eight months that sent shares of once high-flying technology stocks tumbling. Another reason of this decline might be America’s escalating trade war with China.
HII HVT HVT.A WERN EME
Chicago, IL – October 11, 2018 – Zacks Equity Research Chevron (CVX - Free Report) as the Bull of the Day, Outfront Media (OUT - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Boeing Co. (BA - Free Report) , Lockheed Martin Corp. (LMT - Free Report) and Huntington Ingalls Industries, Inc. (HII - Free Report) .
LMT TSCO TOL HII STLD BOE CVX BA OUT
General Dynamics Corp.’s (GD - Free Report) Land Systems unit, recently entered into a strategic partnership with AeroVironment, Inc. (AVAV - Free Report) to jointly develop advanced unmanned aircraft systems (UAS) and tactical missile systems (TMS). Notably, these weaponries will get incorporated in armored ground combat vehicles. While AeroVironment is one of the leading manufacturers of a variety of commercial drones and loitering missile systems, General Dynamics’ Land Systems unit specializes in manufacturing ground combat vehicles.
GD HII HEI.A HEI AVAV
NEWPORT NEWS, Va., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) will release its third quarter 2018 financial results on Thursday, Nov. 8 and host an earnings conference call at 9 a.m. EST the same day. The call will be webcast live on HII’s website: http://www.huntingtoningalls.com.
Chicago, IL – October 11, 2018 - Stocks in this week’s article are Huntington Ingalls Industries, Inc. (HII - Free Report) , WellCare Health Plans, Inc. (WCG - Free Report) , Steel Dynamics, Inc. (STLD - Free Report) , Nucor Corp. (NUE - Free Report) and CBRE Group, Inc. (CBRE - Free Report) .
STZ.B HII STLD CBG WCG STZ URBN CBRE NUE
General Dynamics Corp.’s (GD - Free Report) Land Systems business unit recently secured a $25 million contract for upgrading Stryker flat-bottom vehicles to the Double V-Hull configurated version. Work related to the deal is scheduled to be completed by Apr 30, 2021.
GD HII HEI.A SYK HEI CW
L3 Technologies, Inc. (LLL - Free Report) recently clinched a contract worth $454 million for delivering the next-generation WESCAM MX-10D electro-optical/infrared (EO/IR) and laser designator sensor suite to the U.S. Army. Originally a five-year contract, the U.S. Army will be given an option to extend contract validation for an additional five years, if required. What’s WESCAM MX-10D Sensors? L3 Technologies’ WESCAM MX-10D sensors are primarily effective for low-altitude tactical surveillance, target acquisition and designation missions requiring low-weight installation flexibility.
HII HEI.A HEI FLIR
Wall Street commenced trading in October on a negative note following a robust third-quarter 2018. Rising yields on government bonds and trade-related conflicts with China are major issues, which in turn are leading to volatility. However, the recent stock market volatility may be transitory in nature, given the strong economic fundamentals of the United States. Whatever may be the fact, investors should be prepared to minimize fluctuations in their portfolio and rebalance it with suitable financial assets to maintain stability.
HII RNR WDR SAVE
The Boeing Company (BA - Free Report) recently secured a contract to remanufacture eight and procure nine new-build Apache AH-64E aircraft. Work related to the deal is scheduled to be completed by Feb 28, 2023.
LMT HII BOE TXT BA
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HII / Huntington Ingalls Industries, Inc. on message board site Silicon Investor.
|T-3 Energy (formerly IHII)||T-3 Energy (formerly IHII)||T-3 Energy (formerly IHII)||Highland Holdings Intu0027l - HHII||Highland Holdings Intu0027l - HHII||Highland Holdings Intu0027l - HHII|
as of ET